Follow us:

For Investors




  • InspireMD addresses a growing, $1.8B market
  • Target market has limited competition
  • Aging population and desire for less invasive therapies create favorable growth demographics


InspireMD to host a conference call at 8:30 a.m. ET on Tuesday, October 14th to review these updates on its MGuard Prime coronary EPS and business outlook.

A live webcast will be available. Please click on the following link:

U.S. Dial-in: (877) 407-0784

International Dial-in: (201) 689-8560



InspireMD Ltd. is a high growth medical device company focusing on the development and commercialization of its proprietary stent platform technology: MGuard™.


InspireMD has created a unique, patent-pending mesh net technology that wraps a stent, providing embolic protection (preventing Major Adverse Cardiac Events (MACE) by filtering debris) and reducing vessel injury by spreading strut pressure. MGuard™ is delivered with no change to the current procedure and is well-accepted by physicians. MGuard™ has been implanted in thousands of patients, and in clinical trials it has shown a more than 50% reduction in MACE compared with traditional bare metal stents.

ASTUDIO | Design & Development